Microbot Medical Inc. (NASDAQ:MBOT - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Microbot Medical in a report released on Tuesday, June 10th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company will post earnings per share of ($0.07) for the quarter. HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Microbot Medical's current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical's Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.23) EPS.
Separately, Wall Street Zen raised Microbot Medical from a "sell" rating to a "hold" rating in a report on Saturday.
Get Our Latest Research Report on MBOT
Microbot Medical Price Performance
Shares of MBOT traded down $0.14 during midday trading on Wednesday, hitting $2.34. 1,334,092 shares of the company traded hands, compared to its average volume of 1,738,818. The stock has a 50-day moving average of $2.46 and a 200-day moving average of $1.87. Microbot Medical has a one year low of $0.82 and a one year high of $3.38. The firm has a market cap of $85.12 million, a P/E ratio of -2.92 and a beta of 1.14.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.07.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. purchased a new stake in Microbot Medical in the first quarter worth approximately $57,000. Virtu Financial LLC bought a new position in Microbot Medical in the first quarter worth $42,000. Renaissance Technologies LLC bought a new position in Microbot Medical in the fourth quarter worth $118,000. Finally, Geode Capital Management LLC raised its position in shares of Microbot Medical by 7.9% in the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock worth $160,000 after purchasing an additional 10,442 shares during the last quarter. Hedge funds and other institutional investors own 16.30% of the company's stock.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Featured Articles
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
